These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens. Krishnappa V, Gupta M, Elrifai M, Moftakhar B, Ensley MJ, Vachharajani TJ, Sethi SK, Raina R. Ther Apher Dial; 2018 Apr; 22(2):178-188. PubMed ID: 29250893 [Abstract] [Full Text] [Related]
7. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report. Yamamoto T, Watarai Y, Futamura K, Okada M, Tsujita M, Hiramitsu T, Goto N, Narumi S, Takeda A, Kobayashi T. Transplant Proc; 2017 Apr; 49(1):159-162. PubMed ID: 28104125 [Abstract] [Full Text] [Related]
10. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Kato H, Miyakawa Y, Hidaka Y, Inoue N, Ito S, Kagami S, Kaname S, Matsumoto M, Mizuno M, Matsuda T, Shimono A, Maruyama S, Fujimura Y, Nangaku M, Okada H. Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568 [Abstract] [Full Text] [Related]
11. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Frémeaux-Bacchi V. Am J Kidney Dis; 2014 Jan; 63(1):40-8. PubMed ID: 24021908 [Abstract] [Full Text] [Related]
13. Relapse of Atypical Hemolytic Uremic Syndrome During Pregnancy in a Patient on Eculizumab Maintenance Treatment: A Case Report. Fontana F, Alfano G, Bardhushi E, Ligabue G, Giovanella S, Neri I, Cappelli G. Am J Case Rep; 2019 Oct 04; 20():1460-1465. PubMed ID: 31582717 [Abstract] [Full Text] [Related]
18. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis. Gäckler A, Schönermarck U, Dobronravov V, La Manna G, Denker A, Liu P, Vinogradova M, Yoon SS, Praga M. BMC Nephrol; 2021 Jan 06; 22(1):5. PubMed ID: 33407224 [Abstract] [Full Text] [Related]
20. Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report. Kourouklaris A, Ioannou K, Athanasiou I, Panagidou A, Demetriou K, Zavros M. J Med Case Rep; 2014 Sep 14; 8():307. PubMed ID: 25219386 [Abstract] [Full Text] [Related] Page: [Next] [New Search]